FDA drops boxed warnings on menopause hormones

The FDA on Nov. 10 removed the boxed warning from more than 20 estrogen and progestin products used to treat menopause symptoms, citing evidence that risks are low when therapy starts before age 60 or within 10 years of menopause. The agency published revised prescribing information and a JAMA commentary by Commissioner Marty Makary, while noting ongoing debate and limiting use in women with complicating risks; HHS highlighted a shift toward more nuanced, evidence‑based risk communication.